Biodesix Inc reports results for the quarter ended June 30 - Earnings Summary

• Biodesix Inc BDSX.OQ reported a quarterly adjusted loss of 8 cents​​ per share for the quarter ended June 30, identical to the same quarter last year. The mean expectation of six analysts for the quarter was for a loss of 7 cents per share. Wall Street expected results to range from -8 cents to -5 cents per share.

• Revenue rose 11.7% to $20.02 million from a year ago; analysts expected $18.46 million.

• Biodesix Inc's reported EPS for the quarter was a loss of 8 cents​.

• The company reported a quarterly loss of $11.47 million.

• Biodesix Inc shares had risen by 38.2% this quarter and lost 74.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 22% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the healthcare facilities & services peer group is also "buy"

• Wall Street's median 12-month price target for Biodesix Inc is $2.00, about 77.6% above its last closing price of $0.45

This summary was machine generated from LSEG data August 8 at 04:13 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)